Jaume Capdevila
Overview
Explore the profile of Jaume Capdevila including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
170
Citations
5055
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rodriguez-Lloveras H, Zafon C, Iglesias C, Marcos-Ruiz J, Gil J, Rueda-Pujol A, et al.
Thyroid
. 2025 Mar;
PMID: 40045915
Distant metastases (DM) are the leading cause of thyroid cancer-related death in patients with differentiated thyroid cancer (DTC). Despite significant progress in understanding DNA methylation in DTC, the methylation landscape...
2.
Del Olmo-Garcia M, Hernandez-Rienda L, Garcia-Carbonero R, Hernando J, Custodio A, Anton-Pascual B, et al.
Oncologist
. 2025 Feb;
30(2).
PMID: 39998905
Patients with advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) have impaired nutritional and physical performance due to the cancer pathophysiology and its treatment. The NUTRIGETNE study sought to characterize the nutritional status...
3.
Gil-Bernabe S, Garcia-DeLaFuente L, Garcia-Alvarez A, Garcia-Rostan G, Capdevila J, Hernando J
Am J Med Genet C Semin Med Genet
. 2025 Jan;
:e32127.
PMID: 39754491
RET gene is a driver of thyroid cancer (TC) tumorigenesis. The incidence of TC has increased worldwide in the last few decades, both in medullary and follicular-derived subtypes. Several drugs,...
4.
Tissera N, Balconi F, Garcia-Alvarez A, Hernando Cubero J, OConnor J, Chacon M, et al.
Cancer Treat Rev
. 2024 Dec;
132:102863.
PMID: 39721305
Neuroendocrine carcinomas are rare and aggressive malignancies, often diagnosed at advanced stages, leading to poor prognosis. Platinum-based chemotherapy is the standard first-line treatment for advanced neuroendocrine carcinomas; however after achieving...
5.
Ligero M, Hernando J, Delgado E, Garcia-Ruiz A, Merino-Casabiel X, Ibrahim T, et al.
BJC Rep
. 2024 Nov;
1(1):9.
PMID: 39516643
Background: More accurate predictive biomarkers in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are needed. This study aims to investigate radiomics-based tumour phenotypes as a surrogate biomarker of the tumour vasculature...
6.
Mortier L, Villabona L, Lawrence B, Arance A, Butler M, Beylot-Barry M, et al.
Am J Clin Dermatol
. 2024 Oct;
25(6):987-996.
PMID: 39377880
Background: The phase III KEYNOTE-913 study was conducted to evaluate the efficacy and safety of pembrolizumab as first-line therapy in patients with advanced Merkel cell carcinoma (MCC). Objective: The aim...
7.
Riesco-Martinez M, Capdevila J, Alonso V, Jimenez-Fonseca P, Teule A, Grande E, et al.
Nat Commun
. 2024 Aug;
15(1):6753.
PMID: 39117670
The prognosis of patients with advanced high-grade (G3) digestive neuroendocrine neoplasms (NENs) is rather poor. The addition of immune checkpoint inhibition to platinum-based chemotherapy may improve survival. NICE-NEC (NCT03980925) is...
8.
Leboulleux S, Kapiteijn E, Litiere S, Schoffski P, Godbert Y, Rodien P, et al.
Front Endocrinol (Lausanne)
. 2024 Jul;
15:1403687.
PMID: 39015176
Background: Nintedanib is a triple-angiokinase inhibitor with potential activity in patients with advanced thyroid cancers, as radioiodine refractory differentiated thyroid cancer (RAIR DTC) and medullary thyroid cancer (MTC). Design: EORTC-1209...
9.
Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz P, et al.
Lancet
. 2024 Jun;
403(10446):2807-2817.
PMID: 38851203
Background: There are currently no standard first-line treatment options for patients with higher grade 2-3, well-differentiated, advanced, gastroenteropancreatic neuroendocrine tumours. We aimed to investigate the efficacy and safety of first-line...
10.
Brose M, Capdevila J, Elisei R, Bastholt L, Fuhrer-Sakel D, Leboulleux S, et al.
Endocr Relat Cancer
. 2024 Jun;
31(8).
PMID: 38828895
The VERIFY study aimed to determine the efficacy of vandetanib in patients with differentiated thyroid cancer (DTC) that is either locally advanced or metastatic and refractory to radioiodine (RAI) therapy....